KACTUS has demonstrated via ELISA & SPR binding assays that their MHC-peptide complexes & loaded peptide-ready MHCs have good binding affinity to TCRs.
RBD-SpyCatcher-mi3 vaccine construct could be a promising candidate for broad protection against SARS-CoV-2 variants, advocating for further clinical testing.